Lexaria Bioscience Corp (NAS:LEXXW)

$ 0.7999 -0.0001 (-0.01%) Market Cap: - Enterprise Value: - PE Ratio: 0 PB Ratio: 4.51 GF Score: 71/100

Lexaria Bioscience Corp Extraordinary Shareholders Meeting Transcript
Oct 10, 2023
Lexaria Bioscience Corp at LD Micro Main Event Transcript
Oct 25, 2022
Lexaria Bioscience Corp at Benzinga Global Small Cap Investor Conference (Virtual) Transcript
Dec 08, 2021
Lexaria Bioscience Corp at Benzinga Virtual Global Small Cap Conference Transcript
May 13, 2021
Lexaria Bioscience CorpScience and partner Altria complete Phase One of the development program Transcript
Jul 17, 2020

Lexaria Bioscience Corp at LD Micro Main Event Transcript

Oct 25, 2022 / 05:30PM GMT

Transcript

Unidentified Participant

Hi, everyone. Welcome. I have George here from Lexaria Bioscience. And take it away.

George JurÄ;iÄ;Lexaria Bioscience Corp.;IR Head

,-

Thank you very much. Thank you, everyone, for joining us today and everyone dialing in virtually. My name is George JurÄiÄ, Head of Investor Relations for Lexaria Bioscience. We do trade on the Nasdaq, LEXX; and we trade tradable warrants as well, LEXXW. We're a drug delivery platform innovator with multiple mainstream applications.

Our disclaimer slide, a lot of fun stuff in there. I'll kick off this presentation with a Lexaria Bioscience at a glance. Lexaria's DehydraTECH is a disruptive patented drug delivery technology that is more effective at delivering active pharmaceutical ingredients into the bloodstream in brain tissue. DehydraTECH is applied to multiple ingestible product format such as tablets, capsules, or suspensions, mouth melts, and more.

Pharmacokinetic or PK studies have shown to deliver more quantities of API in less time for cannabidiol

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.